MOUNTAIN VIEW, Calif., May 18 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, announced today that it has been awarded a patent for interactively building pharmacokinetic and pharmacodynamic (“PK/PD”) models using a graphical interface (U.S. Application No. 7,043,415). The patented graphical interface is already deployed in Pharsight Trial Simulator(TM).
“The Food and Drug Administration’s Critical Path Initiative calls for more PK/PD modeling to streamline drug development and approval,” said Shawn O’Connor, president, CEO, and chairman of Pharsight. “As a result, our pharmaceutical and biotechnology clients must find more productive modeling tools. The graphical and intuitive interface covered by our patent, which we have implemented in Pharsight Trial Simulator, allows them to achieve increased modeling productivity. This means better models, faster learning and improved utilization of scarce modeling personnel.”
The graphical user interface allows users to place and connect objects representing pharmacokinetic and pharmacodynamic elements. As the objects are placed and connected, they are converted into an internal format representing the statements of the corresponding computational model. These statements are actively presented to the user in a summarized form, as the computational model is constructed, to enable immediate verification of the model. This summarized form may be a surface syntax showing key equations that make up the model, or they may be graphs of behavior of one or more user-selected variables. More information on the innovation is available at http://www.uspto.gov/patft/index.html.
About Pharsight Trial Simulator
Pharsight Trial Simulator balances ease-of-use with patented technology for defining and testing interactive drug models, exploring and communicating study design attributes, and performing statistical and sensitivity analysis through graphical and statistical summaries. Trial Simulator models encapsulate existing scientific knowledge, to help the entire clinical development team communicate and test ideas, and plan relevant, effective trials for every phase of clinical testing. Pharsight Trial Simulator helps development teams anticipate risks and preview the range of expected trial results before R&D dollars are committed to further development of a drug, and human subjects are exposed to experimental therapies. Development team members of diverse disciplines use Pharsight Trial Simulator to conduct a series of “what if” simulations comparing different trial, patient and drug activity scenarios. By varying simulation input parameters, development teams can test the impact on trial results of changes in known information, assumptions about the drug and subjects, and variations in the trial design. More information on Trial Simulator is available at http://www.pharsight.com/products/prod_pts_home.php.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Safe Harbor
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the expected benefits to customers from the use of Pharsight’s products. Actual results may differ materially from Pharsight’s expectations due to a variety of factors, including the failure of Pharsight’s products to obtain anticipated levels of customer acceptance or to meet customers’ expectations. Further information on potential factors that could affect actual results is included in Pharsight’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on February 13, 2006. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation. Trial Simulator(TM) is a trademark of Pharsight Corporation.
Pharsight Corporation
CONTACT: investors, Douglas Sherk or Jennifer Beugelmans, +1-415-896-6820,or media, Steve DiMattia, +1-646-277-8706, all of EVC Group, for Pharsight
Web site: http://www.pharsight.com//
